Skip to main content

Table 3 Transition matrix for the treatment pathway metformin+sulfonylureas

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

   To t+1    
   Metformin monotherapy Metformin +SU Metformin +SU + Basal insulin Death
From t Metformin monotherapy # 0.046 0 60–70 years; 0.021
71–80 years; 0.051
81–85 years; 0.107
  Metformin +SU 0 # 0.053 60–70 years; 0.021 × 1.85 (HR)
71–80 years; 0.051 × 1.85 (HR)
81–85 years; 0.107 × 1.85 (HR)
  Metformin +SU + Basal insulin 0 0 # 60–70 years; 0.021
71–80 years; 0.051
81–85 years; 0.107
  Death 0 0 0 1
  1. Acronyms: SU-sulfonylureas, HR-hazard ratio